Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities.
Christov M, Clark AR, Corbin B, Hakroush S, Rhee EP, Saito H, Brooks D, Hesse E, Bouxsein M, Galjart N, Jung JY, Mundel P, Jüppner H, Weins A, Greka A.
Christov M, et al. Among authors: juppner h.
JCI Insight. 2018 Feb 22;3(4):e95091. doi: 10.1172/jci.insight.95091. eCollection 2018 Feb 22.
JCI Insight. 2018.
PMID: 29467330
Free PMC article.